(Q38295850)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

review article

1 reference

title

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1 reference

George Papatheodoridis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Jiannis Vlachogiannakos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

35 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

100-106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

25 February 2020

cites work

1 reference

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

21 January 2018

1 reference

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

Current treatment indications and strategies in chronic hepatitis B virus infection.

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

21 January 2018

1 reference

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

21 January 2018

1 reference

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

21 January 2018

1 reference

Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare

21 January 2018

1 reference

Interferon treatment of chronic hepatitis C with cirrhosis

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B.

21 January 2018

1 reference

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

21 January 2018

1 reference

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.

21 January 2018

1 reference

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

21 January 2018

1 reference

Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.

21 January 2018

1 reference

Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy.

21 January 2018

1 reference

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

21 January 2018

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12719

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25529094%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference